Bristol Myers bags SystImmune’s lung cancer drug for $800M upfront in its third ADC-focused pact of 2023

Bristol Myers Squibb has inked a deal with Chinese-US biotech SystImmune for $800 million upfront for the rights to its Phase I bispecific antibody-drug conjugate targeting both HER3 and EGFR.

SystImmune will develop, commercialize and manufacture the drug candidate, dubbed BL-B01D1, in mainland China through its affiliates, while BMS will…
Click here to view original post

Advertisement — Advertise with Biotech Networks